Hepatic arterial infusion of albumin‑bound paclitaxel plus nedaplatin for breast cancer liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II study gives albumin‑bound paclitaxel (Abraxane) combined with nedaplatin by hepatic arterial infusion on Day 1 of each cycle to patients with breast cancer confined to liver metastases who have failed at least two prior standard therapies. Tumor response in the liver is measured every six weeks using RECIST 1.1, with the primary outcome being liver progression‑free survival and secondary outcomes including liver objective response rate, overall progression‑free survival, and overall survival. The approach delivers higher local chemotherapy concentration to liver lesions while aiming to limit systemic exposure. Eligible patients must have adequate liver function (Child‑Pugh A–B) and ECOG performance status 0–2, and all treatment is performed at the study center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with liver metastases from breast cancer pathologically confirmed via surgery or biopsy.

  * Advanced breast cancer patients with imaging-confirmed visceral tumor burden solely confined to liver metastases.

    * Patients who have previously failed at least two lines of standard therapy (including endocrine therapy, chemotherapy, or targeted therapy), or those for whom researchers determine that local therapy would yield greater benefit.

      * Age 18-70 years.

        * ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2. • 0: Fully active, without any restrictions; • 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work; • 2: Ambulatory and capable of all self-care but unable to carry out any work activities.

          * Liver function score (e.g., Child-Pugh) Class A-B.

            • Class A (5-6 points): Good hepatic reserve, well tolerated to surgery, low incidence of postoperative complications and mortality;

            • Class B (7-9 points): Moderately impaired hepatic reserve, poorly tolerated to surgery, increased postoperative complications and mortality;

            • Class C (≥10 points): Severely impaired hepatic reserve, very poorly tolerated to surgery, high risk of postoperative complications and mortality; surgery is generally not recommended.

            ⑦ Adequate organ function.

            • Hemoglobin ≥90 g/L, white blood cells ≥3.5×10⁹/L, neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L;

            • Serum creatinine ≤1.0×upper normal limit (UNL), and creatinine clearance \>60 mL/min;

            • Alanine aminotransferase (ALT) ≤1.5×UNL, aspartate aminotransferase (AST) ≤1.5×UNL, alkaline phosphatase (ALP) ≤1.5×UNL;

            • Total bilirubin (TBIL) ≤1.5×UNL;

            • No severe abnormalities on electrocardiogram, left ventricular ejection fraction (LVEF) ≥50%;

            • Absence of other severe medical conditions or comorbidities that would preclude tolerance to the clinical trial intervention.
            * Signed informed consent, indicating understanding of the trial's purpose, risks, and potential benefits.

Exclusion Criteria:

1. History of other malignancies.
2. Breast and chest wall recurrence, brain metastases, multiple bone metastases with fracture risk, or visceral metastases outside the liver.
3. Tumor volume ≥70% of liver volume.
4. History of heart failure (NYHA class \>I), myocardial infarction, unstable angina, stroke, or poorly controlled arrhythmia.
5. Active infection, severe allergic reactions, or autoimmune diseases, including but not limited to:

   * Active tuberculosis (TB), currently receiving or having received anti-TB treatment within the past year;
   * HIV infection (HIV1/2 antibody positive);
   * Active hepatitis B or hepatitis C virus infection;
   * History of systemic lupus erythematosus, rheumatoid arthritis, chronic lymphocytic thyroiditis, hyperthyroidism, polyarteritis nodosa, autoimmune hemolytic anemia, etc.
6. Administration of live attenuated vaccines within 4 weeks prior to enrollment or planned during the study period.
7. Uncontrolled hypertension, diabetes, or other serious diseases.
8. Severe uncontrolled dysfunction of the liver, kidneys, lungs, or other vital organs.
9. Pregnant or lactating patients.
10. History of mental illness.
11. Known allergy to albumin-bound paclitaxel, nedaplatin, or related drugs.
12. Current participation in another clinical trial.

Where it's running

• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xaolin Li
• Email: 847678911@qq.com
• Phone: 8615024437258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional health and outcomes for advanced liver cancer patients receiving HAIC plus targeted therapy and immunotherapy

  We will see if baseline emotional status (depressive versus non‑depressive) changes treatment outcomes in adults with BCLC stage B/C hepatocellular carcinoma getting hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07436845

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Can hepatic artery infusion chemotherapy enable liver surgery for colorectal cancer that has spread to the liver?

  This study tests whether hepatic artery infusion chemotherapy plus standard chemotherapy can make some inoperable colorectal liver metastases operable in patients.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07764497

• Electrochemotherapy for unresectable visceral tumors including liver metastases

  This will try electrochemotherapy with bleomycin in adults who have unresectable primary or metastatic visceral tumors, such as liver metastases.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06753136

• Evaluating a new immuno-adjuvant for colorectal liver metastases after ablation treatments

  This study is testing a new treatment called IP-001 to see if it can boost the immune response and help people with colorectal liver metastases feel better after they have undergone ablation therapies.

  Recruiting Phase 1/2 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06630624

• Comparing simultaneous and staged surgery for colorectal cancer with liver metastases

  This study is testing whether doing surgery for colon cancer and liver tumors at the same time or in separate stages is better for patients in terms of recovery and overall health.

  Recruiting Oslo University Hospital · Oslo · NCT06200831

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.